Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Niraparib + VX-803|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Niraparib||Zejula||MK4827||PARP Inhibitor (Pan) 25||Zejula (niraparib) binds and inhibits PARP, which may result in accumulation of DNA damage and apoptosis of tumor cells (PMID: 23810788). Zejula (niraparib) is FDA-approved as maintenance therapy in patients with recurrent or newly-diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy, and in ovarian, fallopian tube, or primary peritoneal cancer that received 3 or more chemotherapies and is homologous recombination deficient as indicated by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and progressed 6 months or more after response to last platinum-based chemotherapy (FDA.gov).|
|VX-803||M4344|VX80||ATR Inhibitor 13||VX-803 (M4344) is an inhibitor of ATR that is used in combination with radiation or chemotherapy (PMID: 30645202, PMID: 31836456).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04655183||Phase Ib/II||Niraparib + VX-803 Niraparib||Study of M4344 in Combination With Niraparib||Withdrawn||0|
|NCT04149145||Phase I||Niraparib + VX-803||Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer||Not yet recruiting||USA||0|